Internal auditor appointed; board also clears state shift and Rs.50 crore limits
Parmax Pharma's board met on November 14, 2026 and approved five items.
By ScoutQuest · · 2 min read
- Internal Auditor Appointed
- M/s. Bakul V. Ganatra & Co, Chartered Accountants (FRN: 0100915W), for Financial Year 2026-2027
- Registered Office Shift
- from Gujarat to Maharashtra, with change in Memorandum of Association — subject to shareholder approval
- Limit Enhancements
- Rs.50 crores each for mortgage/charge on assets and for borrowings — subject to shareholder approval
Board meeting of November 14, 2026
The meeting ran from 06:30 PM to 08:00 PM IST and covered five approved items plus one agenda that was carried over.
What the board approved
- Appointment of M/s. Bakul V. Ganatra & Co, Chartered Accountants (FRN: 0100915W), as Internal Auditor of the Company for the Financial Year 2026-2027. The firm is based in Rajkot, Gujarat.
- Shifting of the registered office from the State of Gujarat to the State of Maharashtra, with Clause II of the Memorandum of Association changed accordingly. This is subject to shareholder approval and other statutory and regulatory approvals.
- Enhancing the limits for sale, creation of mortgage or charge on the company's assets, properties or undertakings up to Rs.50 crores, subject to shareholder approval.
- Increasing the borrowing limits available to the board up to Rs.50 crores, subject to shareholder approval.
- A variation in the terms of the utilisation of preferential issue proceeds, subject to shareholder approval.
Results agenda carried over
The agenda of considering and approving the un-audited financial results for the quarter and half year ended September 30, 2026 was not taken up and approved, and the board meeting was adjourned for this agenda.
What these mean for a retail investor
- An internal auditor is part of the company's internal financial checks; a fresh appointment for the year is an annual housekeeping step.
- The two Rs.50 crore items are ceilings the board is seeking. They set the maximum room available; shareholder approval is still required before they take effect.
- A registered office shift to another state changes the state in which the company is registered. It needs shareholder and regulatory clearances, so it will not happen immediately.
- Variation in the terms of how preferential issue proceeds are used can change the purpose the money was raised for. The terms are subject to shareholder approval.
- The results agenda was not taken up and the meeting was adjourned on that item.
Also from Parmax Pharma
Standalone results for the quarter Ended 30.09.2026
16 Nov 2026
Board approves registered office shift to Maharashtra, Rs.50 crore charge and borrowing limits
14 Nov 2026
Board meeting for Sept quarter results postponed, rescheduled to November 14
13 Nov 2026
More numbers
- Approved limit for mortgage or charge on assetsRs.50 crores
- Approved borrowing limit for the BoardRs.50 crores
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.